HUANGSHI FUERTAI PHARMACEUTICAL TECH CO., LTD
HUANGSHI FUERTAI PHARMACEUTICAL TECH CO., LTD is a Chinese entity focused on the production and supply of tenofovir intermediates. With more than a decade of development in the field, the company has established itself as a principal supplier for key intermediates such as DESMP, CMIC, RPC, HPA, and PMPA. The organization emphasizes strong production capacity, consistent quality, and reliable on-time delivery to end customers, contributing to its solid position in competitive markets.
The corporation operates through a multi-factory structure. HUANGSHI FUERTAI CHEMICAL CO., LTD acts as the parent company, while HUANGSHI FUERTAI PHARMACEUTICAL TECH CO., LTD serves as the main production base for tenofovir intermediates. In addition, HUBEI FUERJIA PHARMACEUTICAL CHEMICAL CO., LTD operates as a key input material production base. This three-factory framework illustrates a diversified manufacturing footprint designed to support product availability and supply chain resilience across various stages of production.
In terms of product scope, the company concentrates on tenofovir and its intermediates, including DESMP, CMIC, RPC, HPA, and PMPA. These materials support applications in antiretroviral therapy, anti-HIV/AIDS, and anti-HBV segments, aligning the business with critical pharmaceutical manufacturing needs. The company also maintains quality and environmental management practices evidenced by ISO 9001 and ISO 14001 certifications, underscoring its commitment to quality systems and environmental stewardship.
From an operational perspective, HUANGSHI FUERTAI reports production capabilities that include reactors, rectifying towers, boilers, and dryers, among other equipment. This mix of manufacturing infrastructure supports scale and process reliability for intermediate production. The company also highlights market engagement, noting a significant market share in India (approximately 60%) and the United States (around 50%), indicating robust export activity and a diversified customer base.
While the information available provides insight into the company’s manufacturing posture and regional market footprint, it does not detail specific freight, logistics, or transportation services. Potential partners seeking to optimize supply chain movements for pharmaceutical intermediates may consider the company’s documented emphasis on capacity, quality control, and reliable supply timelines as favorable factors when exploring logistics partnerships or contract manufacturing logistics arrangements.
For readers of FreightCue, this profile highlights HUANGSHI FUERTAI’s core competency in producing specialized pharmaceutical intermediates, their multi-factory structure, and their established ISO certifications and global market reach. These elements may influence freight forwarders’ considerations regarding temperature-controlled handling, regulatory compliance, cross-border shipments, and timely coordination with suppliers to ensure continuity of supply in international markets.
